Anthera Announces First Quarter 2013 Financial Report and Conference Call
HAYWARD, Calif., May 3, 2013 /PRNewswire/ — Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company focused on developing and commercializing products to treat autoimmune diseases, will release its first quarter 2013 financial report after market close on Monday, May 13(th). Anthera will host a Corporate Update conference call on May 20(th), 2013.
Conference Call Access:
Date: Monday, May 20(th), 2013
Time: 5:00 pm Eastern Time
Domestic Dial-in: (877)312-8807
International Dial-in: (253)237-1190
Conference ID: 64577060
To access the 24-hour audio replay, U.S. and Canadian participants may dial (855)859-2056; international participants may dial (404)537-3406. The conference ID for the replay is 64577060. The audio replay will be available until May 27(th), 2013.
About Anthera Pharmaceuticals
Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products to treat autoimmune diseases. Anthera’s Phase 3 development product candidate, blisibimod, targets elevated levels of B-cell activating factor, or BAFF, which has been associated with a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), or lupus, Immunoglobin A nephropathy, or IgAN, lupus nephritis, vasculitis, rheumatoid arthritis, idiopathic thrombocytopenia purpura, and others.
CONTACT: Dennis Lutz of Anthera Pharmaceuticals, Inc., email@example.com or 510-856-5598.
SOURCE Anthera Pharmaceuticals, Inc.